HIV / AIDS in the News

Mount Sinai Researchers Develop Method to Identify Dormant Cells That Carry HIV - Mount Sinai

 

Curing HIV—How Far Have We Come? - amfAR, The Foundation for AIDS Research

 

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP - BioSpace

 

BPHC Launches Campaign to Raise Awareness of HIV Treatment Resources - Beacon Hill Times

 

Bridging Gaps in HIV Care Through Pharmacy-Based Solutions - AJMC.com Managed Markets Network

 

IL proposal could remove insurance companies from blocking HIV medication - WAND

 

Frailty, Housing Instability Drive Mortality Risk in People With HIV - AJMC.com Managed Markets Network

 

ViiV to pursue six-month dosing for HIV antibody after positive Phase II readout - FirstWord Pharma

 

Long-Acting Injectable Cabotegravir Effective in Both ART, PrEP - AJMC.com Managed Markets Network

 

GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study - Benzinga

 

Merck & Co. moves closer to FDA filing for HIV therapy that maintains viral suppression - FirstWord Pharma

 

At CROI conference, HIV activists sound alarm on Trump policies - Bay Area Reporter, America's highest circulation LGBT newspaper

 

Gilead Presents New HIV Treatment And Cure Research Data - AOL

 

Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs - Medical Xpress

 

CROI 2025 HIV Funding Cuts - Specialty Pharmacy Continuum

 

Tecovirimat Is Safe but Ineffective as Treatment for Clade II Mpox - HIV.gov

 

ViiV announces new study data showing zero HIV cases with Apretude - TipRanks

 

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP - Business Wire

 

ACTG Presents Important Findings from REPRIEVE at CROI 2025 - GlobeNewswire

 

ACTG Presents Study at CROI Demonstrating Potential of - GlobeNewswire

 

Our global anti-AIDS program has saved millions of lives — improve it, don’t kill it - The Hill

 

Researchers make case against Gilead in HIV product hopping fight - Endpoints News

 

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive - Zacks Investment Research

 

The FRESH Study Tests New HIV Remission Strategy in South African Women - Contagionlive.com

 

Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025 - Yahoo Finance

 

People with HIV in Malawi face greater risk for dementia - Medical Xpress

 

Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data - Simply Wall St

 

Merck releases positive phase 3 data on daily oral HIV drug (MRK:NYSE) - Seeking Alpha

 

Impact of US funding freeze on HIV programmes in Kazakhstan - UNAIDS

 

Universal Syphilis Screening in the ED Catches More Cases - Medpage Today